Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Weight Reduction

  • Home
  • Weight Reduction
Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis
Posted inDiabetes & Endocrinology Gastroenterology news

Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis

Posted by MedXY By MedXY 08/04/2026
This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.
Read More
  • Determinants of Endothelial Cell Density One Year After DMEK: Insights from the Diabetes Endothelial Keratoplasty Study
  • Evaluating Dried Blood Spot PCR for Detecting Congenital Cytomegalovirus in Newborns Identified by Targeted Testing
  • Bridging the Mental Health Care Gap for Trauma Patients at Risk of PTSD: Insights from Social Workers
  • End-Organ Damage in Primary Hyperparathyroidism: Prevalence, Progression, and Treatment Gaps in a National Cohort
  • AMBUSH-AI: Advancing Burn Depth Diagnosis with Artificial Intelligence and Ultrasound Imaging
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in